Revvity, Inc. reported a revenue increase of $101.1 million, or 4%, for the fiscal year ending December 28, 2025, totaling $2.86 billion compared to $2.76 billion in the previous year. The Diagnostics segment contributed significantly to this growth, with a revenue increase of $68.5 million, or 5%, driven by strong performance in Immunodiagnostics and Reproductive Health. The Life Sciences segment also saw a revenue increase of $32.5 million, or 2%, primarily due to growth in its Software business. However, the company's gross margin decreased by 104 basis points to 54.8%, attributed to increased tariffs, unfavorable foreign exchange rates, and shifts in product mix.
In terms of operational changes, Revvity made strategic adjustments to its organizational structure, integrating its Applied Genomics business into the Life Sciences segment. This restructuring is part of a broader strategy to enhance operational efficiency and streamline product offerings. The company also focused on innovation, investing in research and development, which saw expenses rise by 10% to $215.8 million. The total employee count as of December 28, 2025, was approximately 11,000, with a significant portion of the workforce based outside the United States.
Revvity's financial health remains strong, with cash and cash equivalents totaling $919.9 million at the end of the fiscal year. The company has a robust stock repurchase program, having repurchased 7.26 million shares for $695.4 million during the fiscal year. The board declared a quarterly dividend of $0.07 per share, consistent with previous quarters, reflecting a commitment to returning value to shareholders. However, the company noted that future dividends may be adjusted based on capital needs for growth and investments.
Looking ahead, Revvity anticipates continued growth driven by its diverse product portfolio and strategic investments in technology and innovation. The company is focused on expanding its market presence, particularly in international markets, where it generates a significant portion of its revenue. Despite facing challenges such as fluctuating foreign exchange rates and increased tariffs, Revvity's management remains optimistic about its long-term growth trajectory and operational efficiency improvements.
About REVVITY, INC.
Revvity, Inc. is a global provider of health science solutions, offering products and services in life sciences and diagnostics. Its core activities include developing technologies for research, drug discovery, and clinical diagnostics, serving pharmaceutical, biotech, healthcare, and research markets worldwide. The company focuses on innovation, strategic acquisitions, and operational excellence to deliver workflows, reagents, instruments, and software that advance healthcare and scientific discovery.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.